AbbraTech Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$8.51M
- Investors
-
4
AbbraTech General Information
Description
Developer of an antibody discovery and development services platform designed to produce high-affinity recombinant proteins. The company's services include antigen and project design, recombinant antibody development, antibody optimization, and antibody production, enabling clients to address the current problems in the antibody development paradigm.
Contact Information
Website
www.abbratech.comCorporate Office
- 25 Business Park Drive
- Suite C
- Branford, CT 06405
- United States
Corporate Office
- 25 Business Park Drive
- Suite C
- Branford, CT 06405
- United States
AbbraTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 06-Feb-2024 | $8.51M | Completed | Generating Revenue | ||
| 4. Seed Round | 29-Jun-2022 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jun-2022 | Completed | Generating Revenue | |||
| 2. Grant | 01-Apr-2022 | $339K | $3.65M | Completed | Generating Revenue | |
| 1. Seed Round | 04-Mar-2021 | $3.65M | $3.65M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AbbraTech Patents
AbbraTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4656203-A1 | Compositions and methods for optimized igg production | Pending | 02-Jun-2024 | ||
| US-20250369983-A1 | Compositions and methods for optimized igg production | Pending | 02-Jun-2024 | ||
| EP-4608446-A1 | Chimeric antibodies and methods of making and using same | Pending | 26-Oct-2022 | ||
| US-20260139036-A1 | Chimeric antibodies and methods of making and using same | Pending | 26-Oct-2022 | ||
| WO-2024092073-A1 | Chimeric antibodies and methods of making and using same | Inactive | 26-Oct-2022 | C07K16/1145 |
AbbraTech Signals
AbbraTech Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Meltwind Advisory | Venture Capital | Minority | ||
| Elm Street Ventures | VC-Backed Company | Minority | ||
| National Institutes of Health | Government | |||
| Connecticut Innovations | Venture Capital | Minority |
AbbraTech FAQs
-
When was AbbraTech founded?
AbbraTech was founded in 2020.
-
Where is AbbraTech headquartered?
AbbraTech is headquartered in Branford, CT.
-
What is the size of AbbraTech?
AbbraTech has 7 total employees.
-
What industry is AbbraTech in?
AbbraTech’s primary industry is Biotechnology.
-
Is AbbraTech a private or public company?
AbbraTech is a Private company.
-
What is AbbraTech’s current revenue?
The current revenue for AbbraTech is .
-
How much funding has AbbraTech raised over time?
AbbraTech has raised $13.8M.
-
Who are AbbraTech’s investors?
Meltwind Advisory, Elm Street Ventures, National Institutes of Health, and Connecticut Innovations have invested in AbbraTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process